Aubrey Rankin is President at Revance Therapeutics, Inc. (RVNC). They have made 10 open-market trades across 1 company since 2020, most recently 2022-03-15.
CIK 0001818576
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $433K since 2021, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RVNC | 94,091 | $343K |
Shares reported on the most recent Form 4, priced at the 2022-03-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RVNC | BUY | 2021-12-03 | 2021-12-06 | $14.43 | $433K | +5.4% | +1.0% | -1.8% |
| RVNC | SELL | 2021-08-16 | 2021-08-17 | $26.34 | $493K | +5.5% | +2.4% | -45.0% |
| RVNC | SELL | 2021-07-28 | 2021-07-30 | $30.06 | $1.6M | -8.9% | -7.7% | -52.7% |
| RVNC | SELL | 2021-07-26 | 2021-07-28 | $29.72 | $3.3M | -6.7% | -9.5% | -53.5% |
| RVNC | SELL · 10b5-1 | 2021-04-05 | 2021-04-06 | $28.28 | $57 | -1.8% | +0.9% | +15.6% |
| RVNC | SELL | 2021-03-04 | 2021-03-05 | $25.43 | $1.7M | +6.2% | +6.7% | +7.4% |
| RVNC | SELL | 2021-02-01 | 2021-02-03 | $25.95 | $1.7M | +4.9% | -6.7% | -0.6% |
| RVNC | SELL | 2020-12-30 | 2021-01-04 | $27.82 | $1.8M | +6.6% | +4.4% | +4.9% |
| RVNC | SELL | 2020-11-30 | 2020-12-02 | $23.85 | $1.6M | +10.1% | +13.4% | +8.4% |
| RVNC | SELL | 2020-10-29 | 2020-10-30 | $26.15 | $1.7M | +3.0% | -6.4% | +1.6% |
| RVNC | SELL | 2020-09-28 | 2020-09-30 | $26.18 | $1.7M | +10.0% | +2.5% | +8.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.